DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Wuyts WA, Kolb M, Stowasser S. et al.
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
Lung 2016;
194: 739-743
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.